Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Etomoxir A3404 for Reliable Metabolic Assays
2026-09-01
Learn how Etomoxir (SKU A3404) can improve interpretation of viability, proliferation, cytotoxicity, and immunometabolic assays by providing a defined CPT-1 perturbation. This scenario-based guide covers concentration selection, solvent handling, whole-blood compatibility, data interpretation, and practical product-selection criteria.
-
Irinotecan Workflows for Colorectal Cancer Research
2026-09-01
Build more interpretable irinotecan experiments by separating prodrug activation, topoisomerase I–linked DNA damage, and downstream cell death. This workflow guide covers cell-based screening, xenograft translation, assay timing, solubility control, and troubleshooting for reproducible colorectal cancer research.
-
Tiamulin (Thiamutilin): Mechanism & Use
2026-08-31
Tiamulin, also called Thiamutilin, is a semi-synthetic pleuromutilin antibiotic used mainly in pigs and poultry. It inhibits bacterial protein synthesis at the 50S ribosomal subunit and has separately reported anti-inflammatory activity, but dosing, residue control, and species-specific evidence remain essential.
-
Prunin Targets Senecavirus A IRES-Dependent Replication
2026-08-31
The reference study reports that prunin suppresses Senecavirus A replication in cell culture and an animal model, with evidence implicating the viral internal ribosome entry site as a mechanistic target. Its main contribution is to connect an antiviral phenotype with a defined translation-control element, while also highlighting the need for orthogonal replication, toxicity, and in vivo validation.
-
Macrophage Depletion as a Test of Liver Repair
2026-08-30
A translational framework for using Clodronate Liposomes to test whether macrophage states are causal drivers of hepatic ischemia-reperfusion injury, rather than merely correlates identified by single-cell analysis.
-
Biomarkers Sharpen In Vitro Micronucleus Assays
2026-08-29
Avlasevich and colleagues combined flow-cytometric micronucleus scoring with DNA damage-response biomarkers to distinguish bona fide genotoxicity from irrelevant positive results associated with cytotoxicity. In a reference-chemical panel, requiring concordant micronucleus and biomarker responses markedly improved specificity while preserving sensitivity, creating a more informative framework for mode-of-action and potency assessment.
-
(Z)-4-Hydroxytamoxifen in Relapse Assays
2026-08-28
Explore how (Z)-4-Hydroxytamoxifen can sharpen estrogen receptor experiments while clarifying the biological limits of proliferation-ablation relapse models. This article connects ER pharmacology, assay design, and recurrence biology without treating distinct mechanisms as interchangeable.
-
LDN-193189: BMP Signaling and Cell Plasticity
2026-08-28
LDN-193189 is an ALK inhibitor that enables receptor-level dissection of BMP signaling alongside TGF-β-driven epithelial plasticity. This guide translates mechanistic findings on Sca-1 regulation into practical assay designs, controls, and interpretation strategies.
-
HyperScribe T7 High Yield RNA Synthesis Kit Workflow
2026-08-27
Build a reliable T7 transcription workflow for long, labeled, capped, or modified RNA, with practical controls for yield and quality. The guide also translates a recent LINC02613–LCP1 metastasis study into actionable RNA probe, pull-down, and interference-assay choices.
-
γH2AX: Turning DNA Damage Into Translational Insight
2026-08-27
A mechanistic and strategic guide to using γ-H2AX as a DNA damage biomarker in radiosensitizer development, FLASH-RT research, apoptosis studies, and translational DNA damage and repair research.
-
Filipin III Workflows for Membrane Cholesterol
2026-08-26
Filipin III converts membrane sterol organization into an imaging-ready readout, supporting cholesterol detection in membranes, vesicle assays, and ultrastructural validation. This practical guide connects staining design with a recent SOAT1–lipophagy pulmonary fibrosis study while emphasizing controls, reagent stability, and interpretation limits.
-
EdU Imaging Kits (Cy3) for S-Phase Research
2026-08-26
EdU Imaging Kits (Cy3) convert DNA replication into a bright, quantifiable Cy3 signal for microscopy and flow cytometry without harsh DNA denaturation. The workflow is especially useful for testing how LmPLK1 perturbation affects proliferating intestinal cells in Locusta migratoria while preserving morphology and antigen-accessible samples.
-
Ruxolitinib, DRP1, and ATC Cell Death
2026-08-25
A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 activity, DRP1-dependent mitochondrial fission, and coordinated apoptosis plus GSDME-associated pyroptosis in anaplastic thyroid carcinoma. The work supports mitochondrial dynamics as an actionable downstream readout of JAK/STAT signaling pathway modulation, while remaining preclinical and disease-context specific.
-
m6A Antagonism in Plant–Virus Interactions
2026-08-25
The reference study identifies RNA m6A modification as a dynamic battleground between Arabidopsis and Cucumber mosaic virus (CMV). It shows that host methyltransferases and the ECT8 reader promote viral RNA destabilization, whereas the CMV 2b protein disrupts m6A deposition and alters host defense transcripts.
-
Mdivi-1 Maps DRP1-Dependent Cell Crosstalk
2026-08-24
Mdivi-1 is a selective DRP1 inhibitor that can reveal how mitochondrial fission connects intercellular signaling to apoptosis. This article applies the compound to conditioned-medium experiments inspired by hypoxia pulmonary hypertension research and explains how to interpret pathway-level evidence.